ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, T.
Right arrow Articles by Esato, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, T.
Right arrow Articles by Esato, K.
Related Collections
Right arrow Lung - basic science

Ann Thorac Surg 2001;72:1173-1178
© 2001 The Society of Thoracic Surgeons

Original article: general thoracic

Digitonin enhances the antitumor effect of cisplatin during isolated lung perfusion

Toshiki Tanaka, MDa, Yoshikazu Kaneda, MDa, Tao-Sheng Li, MDa, Takahisa Matsuoka, MDa, Nobuya Zempo, MDa, Kensuke Esato, MDa

a First Department of Surgery, Yamaguchi University School of Medicine, Yamaguchi, Japan

Accepted for publication June 18, 2001.

Address reprint requests to Dr Tanaka, First Department of Surgery, Yamaguchi University School of Medicine, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan
e-mail: toshik{at}po.cc.yamaguchi-u.ac.jp

Background. The antitumor effect of isolated lung perfusion with cisplatin was limited because the intracellular platinum concentration did not increase sufficiently. To solve this problem, digitonin, a detergent, was chosen to increase cell permeability and enhance intracellular uptake and antitumor effect. This study was designed to investigate toxicity, pharmacokinetics, and efficacy of isolated lung perfusion with the combined use of digitonin and cisplatin in Fischer 344 rats.

Methods. Systemic and local toxicities of isolated lung perfusion treatment were evaluated on the basis of body weight change, survival rate, and histologic findings. The maximal tolerated dose of digitonin was determined by assessing survival on day 21 after contralateral pneumonectomy, body weight change, and histologic findings. Pharmacokinetics were observed in a solitary lung tumor nodule model by measuring platinum concentration in tumor and normal lung tissue. The antitumor effect was evaluated by the number of tumor nodules in the left lung 21 days after isolated lung perfusion. Isolated lung perfusion was performed 7 days after 1.0 x 106 methylcholanthrene sarcoma cells were injected into the external jugular vein.

Results. The maximal tolerated dose of digitonin was 20 µmol/L. Platinum concentration of tumor nodules in the digitonin-cisplatin–treated rats was 20% higher than in the cisplatin-only group (5.48 ± 0.64 µg/g tissue versus 4.50 ± 1.09 µg/g tissue; p = 0.067). The number of pulmonary nodules decreased significantly by digitonin use (1.3 ± 1.5 versus 9.7 ± 2; p < 0.0001).

Conclusions. Isolated lung perfusion with digitonin and cisplatin in combination was performed safely and enhanced the antitumor effect. These drugs in combination show promise for enhancing the effect of clinical isolated lung perfusion.




This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
P. E. Van Schil, J. M. Hendriks, B. P. van Putte, B. A. Stockman, P. R. Lauwers, P. W. ten Broecke, M. J. Grootenboers, and F. M. Schramel
Isolated lung perfusion and related techniques for the treatment of pulmonary metastases
Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 487 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
B. P. v. Putte, A. Huisman, J. M.H. Hendriks, P. E.Y. v. Schil, W. J. v. Boven, F. Schramel, F. Nijkamp, and G. Folkerts
Pulmonary intravascular volume can be used for dose calculation in isolated lung perfusion
Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 594 - 598.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
B. P. Van Putte, J. M.H. Hendriks, S. Romijn, B. Pauwels, J. B. Vermorken, and P. E.Y. Van Schil
Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases
J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 125 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Jinbo, K. Ueda, Y. Kaneda, M. Sudo, T.-S. Li, and K. Hamano
Video-assisted transcatheter lung perfusion regional chemotherapy
Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1079 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
U. F.W. Franke, T. Wittwer, M. Kaluza, M. Albert, V. Becker, M. Roskos, M. Lessel, and T. Wahlers
Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue
Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 800 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
C. Schroder, S. Fisher, A. C. Pieck, A. Muller, U. Jaehde, H. Kirchner, A. Haverich, and P. Macchiarini
Technique and results of hyperthermic (41{degrees}C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis
Eur. J. Cardiothorac. Surg., July 1, 2002; 22(1): 41 - 46.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The Society of Thoracic Surgeons.